Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WYETH - Comparison Results

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WYETH AJANTA PHARMA/
WYETH
 
P/E (TTM) x 27.7 27.7 99.9% View Chart
P/BV x 6.8 5.3 127.9% View Chart
Dividend Yield % 0.5 1.3 40.4%  

Financials

 AJANTA PHARMA   WYETH
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
WYETH
Mar-13
AJANTA PHARMA/
WYETH
5-Yr Chart
Click to enlarge
High Rs1,4221,044 136.1%   
Low Rs898818 109.7%   
Sales per share (Unadj.) Rs233.5298.6 78.2%  
Earnings per share (Unadj.) Rs44.057.2 76.8%  
Cash flow per share (Unadj.) Rs52.258.4 89.3%  
Dividends per share (Unadj.) Rs9.0017.00 52.9%  
Dividend yield (eoy) %0.81.8 42.5%  
Book value per share (Unadj.) Rs255.1249.5 102.2%  
Shares outstanding (eoy) m88.0222.72 387.4%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.1 159.2%   
Avg P/E ratio x26.416.3 162.2%  
P/CF ratio (eoy) x22.215.9 139.5%  
Price / Book Value ratio x4.53.7 121.8%  
Dividend payout %20.529.7 68.9%   
Avg Mkt Cap Rs m102,08121,157 482.5%   
No. of employees `0006.80.5 1,382.1%   
Total wages/salary Rs m4,307400 1,076.8%   
Avg. sales/employee Rs Th3,022.613,787.4 21.9%   
Avg. wages/employee Rs Th633.4813.0 77.9%   
Avg. net profit/employee Rs Th569.12,643.3 21.5%   
INCOME DATA
Net Sales Rs m20,5546,783 303.0%  
Other income Rs m211353 59.8%   
Total revenues Rs m20,7657,136 291.0%   
Gross profit Rs m5,6641,617 350.2%  
Depreciation Rs m72127 2,709.8%   
Interest Rs m126 210.9%   
Profit before tax Rs m5,1431,938 265.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,273632 201.4%   
Profit after tax Rs m3,8701,301 297.6%  
Gross profit margin %27.623.8 115.6%  
Effective tax rate %24.832.6 75.9%   
Net profit margin %18.819.2 98.2%  
BALANCE SHEET DATA
Current assets Rs m11,8126,984 169.1%   
Current liabilities Rs m3,7762,056 183.7%   
Net working cap to sales %39.172.6 53.8%  
Current ratio x3.13.4 92.1%  
Inventory Days Days7799 78.0%  
Debtors Days Days8224 340.8%  
Net fixed assets Rs m14,398244 5,893.7%   
Share capital Rs m175227 77.2%   
"Free" reserves Rs m22,2775,441 409.4%   
Net worth Rs m22,4525,668 396.1%   
Long term debt Rs m725 26.4%   
Total assets Rs m26,9627,901 341.2%  
Interest coverage x444.3353.3 125.8%   
Debt to equity ratio x00 6.7%  
Sales to assets ratio x0.80.9 88.8%   
Return on assets %14.416.5 87.1%  
Return on equity %17.222.9 75.1%  
Return on capital %23.034.0 67.4%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m10,68215 70,274.3%   
Fx outflow Rs m2,1022,677 78.5%   
Net fx Rs m8,580-2,662 -322.3%   
CASH FLOW
From Operations Rs m3,748923 406.0%  
From Investments Rs m-2,228317 -703.1%  
From Financial Activity Rs m-1,475-481 306.6%  
Net Cashflow Rs m45759 6.0%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 7.2 105.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 30.4 55.9%  
Shareholders   20,968 21,978 95.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   CIPLA  PFIZER  NATCO PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 15, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS